TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inoviq Ltd ( (AU:IIQ) ) has shared an announcement.
INOVIQ Ltd has successfully completed its share purchase plan, raising a total of A$0.7 million, contributing to a total capital raise of A$10.2 million alongside a recent placement to institutional investors. The funds will be allocated to accelerate the clinical validation and commercialization of the EXO-OC™ ovarian cancer test and to advance the preclinical development of the exosome therapeutic program for solid tumors, potentially enhancing the company’s market position in cancer diagnostics and therapeutics.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology, advancing next-generation diagnostics and therapeutics aimed at transforming cancer care. The company’s product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 164,231
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.57M
For a thorough assessment of IIQ stock, go to TipRanks’ Stock Analysis page.